Receptor of Advanced Glycated End Products Gene Polymorphism in Patients with Rheumatoid Arthritis | ||
| Zagazig University Medical Journal | ||
| Article 25, Volume 30, Issue 1.3, March and April 2024, Pages 207-214 PDF (1.03 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/zumj.2023.230698.2854 | ||
| Authors | ||
| Lamiaa Abdel Wahaab Mohammad1; Ghada S. Nageeb2; Manar Abdullah Soliman Nassar* 1; Safaa M. Elalawi1 | ||
| 1Clinical Pathology Department, Faculty of Medicine, Zagazig University | ||
| 2Rheumatology and rehabilitation Department, Faculty of Medicine, Zagazig University | ||
| Abstract | ||
| Background: Through its capacity to intensify inflammatory pathways, Rheumatoid arthritis (RA) has been connected to the receptor for advanced glycation end products (RAGE). So, in those with rheumatoid arthritis, the RAGE gene polymorphism may be a significant indicator of disease activity. Aim: Illustration of the role of RAGE gene polymorphism (G82S) in susceptibility of rheumatoid arthritis. Subjects and methods: Thirty individuals were used in this case control study, which was conducted at the Zagazig University hospitals' Clinical Pathology, Rheumatology, and Rehabilitation departments after obtaining their written agreement for ethical reasons. The participants were split up into two groups: fifteen RA cases and fifteen healthy volunteers who acted as the control group. A molecular investigation of the RAGE gene's glycine-to-serine (G82S) polymorphism was done for genotyping. Results: Rheumatoid arthritis patients have allele G levels that are 7 times greater than those in the control group, with a 95% CI of 1.38 to 35.5. Significant difference: p=0.009. Conclusion: The RAGE gene polymorphism (G82S) with allele G were higher in rheumatoid arthritis patients than the control group. Sadly, we were unable to discover a link between gene variation and disease activity. | ||
| Keywords | ||
| Rheumatoid arthritis; polymorphism; G82S | ||
|
Statistics Article View: 125 PDF Download: 87 |
||
